Q3 Preview: A Stabilizing Quarter For J&J In China?
This article was originally published in PharmAsia News
Since J&J reported in July a slowdown for its sales for China, the Chinese economy has deteriorated further. Can several new initiatives help the largest U.S. healthcare company to recover in this critical market?
Register for our free email digests: